A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223 (BELFIGO)

Bayer

Status: Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Treatments: Drug: Radium-223 (Xofigo, Bay88-8223)

Study type: Observational

Funder types: Industry

Identifiers

NCT03563014

20239

Details and patient eligibility

About

The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.

Enrollment: 164 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases
• All consecutive patients who started Radium-223 treatment between 22 December 2014 and 01 June 2017
• Availability of medical records during the observation period (22DEC2013 - 01JUN2018)

Exclusion criteria

• Patients treated with Radium-223 for any reason before 22 December 2014 (for example an interventional trial)
• Patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period
• Patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the Radium-223 treatment period

Trial design

164 participants in 1 patient group

Radium-223 (Xofigo, Bay88-8223)

Description:

Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication

Treatment:

Drug: Radium-223 (Xofigo, Bay88-8223)